Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Innexus Biotechnology Inc IXSBF

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

GREY:IXSBF - Post Discussion

View:
Post by Ferrel on Aug 11, 2016 10:25am

still alive

wonder how our collaborators are making out with our tech.
stupid non disclosure agreements killing this stock...... i knew this would happen.
all we can do is wait for one of them to succeed.
why would anybody want to use NDA'S ....that is the dumbest thing you could do.
Comment by Umpolung on Oct 16, 2016 1:26am
Yep. It's still alive on the pinks where it'll actually never die. Looks like your "pump" helped get someone out of a $13 position! Close Prices Last 3 Months Price/volumes not adjusted for restructures png;base64,iVBORw0KGgoAAAANSUhEUgAAAGQAAABkCAAAAABVicqIAAAABGdBTUEAALGPC ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities